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Abstract 
Background: Idiopathic non-histaminergic acquired angioedema (InH-AAE) is a rare disease for which there are no 
available laboratory parameters to clearly define the disorder. Therapy is often difficult and various treatment options 
have been proposed. In this paper, we have evaluated the most effective therapies for InH-AAE on the basis of current 
literature and report the therapeutic effect of omalizumab in three patients with InH-AAE.
Methods: Literature was searched with a combination of MeSH/EMTREE terms and freetext search for angioedema 
and therapy/omalizumab in the databases Medline (Ovid), PubMed/Premedline, Embase, Cochrane library and Sco-
pus with no time or language restrictions. In three patients affected by InH-AAE the therapeutic effect of omalizumab 
was demonstrated by clinical outcome. In one patient the FcεRI receptor density on basophils was monitored under 
therapy with omalizumab.
Results: From the review of the current literature, 25 out of 286 publications dealing with relevant therapeutic rec-
ommendations for InH-AAE were analyzed. Six publications with 98 patients referred to tranexamic acid, of which 27 
had a complete, 70 a partial and 1 no response. In three case reports ecallantide showed 2 patients with a complete 
and 1 a partial response. In four case reports for Icatibant 2 had a complete and 3 a partial response. When evalu-
ated in three reports, C1-INH found complete and partial responses in 2 patients each. One patient had a complete 
response to progestin. Omalizumab was described in 6 reports with 20 patients, all of whom showed a complete 
response. All three patients described in our study responded to omalizumab with a complete remission. Density of 
FcεRI receptors on basophils, monitored in patient 1 on a long-term course of 31 months, decreased from 74,051.61 
to a minimal level of 1907 receptors per cell.
Conclusions: Omalizumab seems to be the most effective therapy in InH-AAE. The continuous decrease of FcεRI-
receptor density on basophils under therapy with omalizumab along with clinical improvement observed in one 
patient, could serve as a new approach for further studies to evaluate FcεRI-receptor density as a surrogate marker for 
therapeutic efficacy and for dosing and determining injection intervals of omalizumab.
Trial registration BASEC-Nr. Req-2016-00692. Retrospectively registered 24.11.2016.
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Background
Angioedema (AE) is defined as a localized swelling of 
the subcutaneous and/or submucosal tissue caused by 
an increase of vascular permeability, which is induced by 
vasoactive mediators [1]. Although most often associated 
with urticaria, angioedema represents its own entity [2, 
3]. According to a recent consensus report, angioedemas 
without urticaria are classified in three hereditary (HAE), 
and four acquired (AAE) forms [4] (Table 1).
Idiopathic AAE are the most frequently occurring 
forms of angioedemas [3–5]. Diagnostic laboratory 
parameters are not yet available for diagnosing and 
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differentiating the two idiopathic acquired forms, Idi-
opathic histaminergic acquired angioedema (IH-AAE) 
and Idiopathic non-histaminergic acquired angi-
oedema (InH-AAE) [6]. Diagnosis of IH-AAE is con-
sidered if the angioedema responds to antihistamines. 
The lack of response to antihistamines defines InH-
AAE [4, 7].
Therapy of InH-AAE is often challenging. This is 
reflected by a wide variety of therapeutic options for 
InH-AAE, such as high dosages of antihistamines (AH), 
icatibant, ecallantide, C1-INH concentrates, glucocorti-
costeroids (GCS), omalizumab, and other agents.
In this study we give an overview of the different and 
most effective therapeutic modalities for InH-AAE 
according the current literature. We further report the 
clinical response of omalizumab in three patients affected 
by InH-AAE. In one patient we monitored the FcεRI-
receptor density of basophils during therapy over a 
period of 31 months.
Methods
The local Ethical Review Board of Zurich assessed the 
design of this observational and retrospective study and 
offered a waiver (Req-2016-00692). The study strictly 
adhered to the principles of good clinical practice and the 
ethical standards outlined in the Declaration of Helsinki 
[8]. All patients were verbally informed and gave their 
written informed consent for this study.
Patients
All three patients suffering from angioedemas for years 
were referred to the out-patient clinic of allergy and 
clinical immunology. After a detailed allergological and 
immunological work up, they were diagnosed as InH-
AAE. Complement factor C4 level, C1 inhibitor level 
and C1 inhibitor function were within the normal range. 
None of them underwent treatment with ACE inhibitors, 
sartans, gliptins or NSAID.
Comprehensive review of the literature
Literature was searched with a combination of MeSH/
EMTREE terms and freetext search for angioedema and 
therapy/omalizumab in the databases Medline (Ovid), 
PubMed/Premedline, Embase, Cochrane library and Sco-
pus with no time or language restrictions. The detailed 
search protocol is shown in Additional file 1.
FcεRI receptor density measurement
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from anticoagulant-treated venous blood by density 
gradient centrifugation using Ficoll Paque (Amersham 
Pharmacia Biosciences, Uppsala, Sweden). The surface 
density of FcεRI on donor basophils was determined by 
means of DAKO  QIFIKIT® (Dako-Cytomation, City, 
Denmark): Freshly isolated PBMCs were resuspended 
in  CellWASH® (BD Bioscience, San Jose, CA, USA) and 
stained with primary mouse monoclonal anti-FcεRI anti-
bodies (eBioscience, San Diego, CA, USA). Subsequently, 
goat anti-mouse fluorescein isothiocyanate (FITC) con-
jugated immunoglobulin F(ab’)2 fragments were added to 
detect bound anti-FcεRI (Dako Denmark, 2008,  QIFIKIT® 
Code K0078). Finally, to identify basophils, staining with 
anti-CCR3-PE (BioLegend, San Diego, CA, USA) was per-
formed. The antibody-binding capacity of basophils was 
determined by the mean fluorescent intensity measured by 
the  FACSCanto® (BD Bioscience, San Jose, CA, USA) flow 
cytometer using a calibration curve set up with beads of 
known antibody concentration from the DAKO  QIFIKIT®.
Results
Comprehensive review of the literature
From the 499 retrieved publications 213 were duplicates. 
Of the remaining 286 publications, 25 trials, consisting of 
case reports, case series and retrospective observational 
studies with relevant therapeutic recommendations for 
InH-AAE, were selected and analyzed.
Six case reports or retrospective trials describe the 
efficacy of tranexamic acid (TA) in InH-AAE. Out of 98 
patients, 27 responded completely, 70 partially, and 1 
patient showed no response [3, 9–13].
Three case reports showed a complete response in 2 
and a partial response in 1 patient treated with ecallan-
tide [14–16]. Therapy with icatibant is described in four 
case reports. A complete response was shown in 2, and a 
partial response in 3 patients [14, 17–19].
In three case reports with C1-INH 2 patients had a 
complete and 2 patients a partial response [14, 19, 20].
In a retrospective study of 50 patients, progestin 
decreased the frequency of angioedema attacks in 45 
women. Twenty of them were affected by idiopathic AE 
and 80% responded with a partial response [21].
Table 1 Forms of Angioedemas without wheals
Modified from Cicardi et al. [4]
Hereditary angioedemas
HAE with C1-inhibitor deficiency (C1-INH_HAE)
HAE with FXII mutations (FXII-HAE)
HAE of unknown origin (U-HAE)
Acquired angioedemas
Idiopathic histaminergic acquired angioedema (IH-AAE)
Idiopathic non-histaminergic acuired angioedema (InH-AAE)
Acquired angioedema related to angiotensin-converting enzyme inhibi-
tor (ACEi-AAE)
Aquired angioedema with C1-inhibitor deficiency (C1-INH-AAE)
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In six reports 20 patients with InH-AAE were treated 
with omalizumab. All had a complete response [22–27].
Five Individual reports with 1 patient each were 
described for ciclosporin with no response [28], dapsone 
[29], fresh frozen plasma [30], rituximab [31] and canna-
bis [32]—all of them with a complete response (Table 2).
Case reports
Patient 1
A 67-year-old white female with a 3-year history of recur-
rent, twice-weekly angioedemas of the lips, tongue and 
larynx. The clinical response of the angioedemas to the 
intake of antihistamines (AH) of doses up to three times 
higher than that normally recommended was not suffi-
cient. Thus, glococorticosteroids (GCS) on a weekly basis 
were often necessary to control the symptoms. Omali-
zumab 150  mg was administered subcutaneously in 
4-week intervals. After the first injection of omalizumab, 
facial swellings improved markedly. Treatment with AH 
and GCS were discontinued after 8 weeks. Omalizumab 
was paused after the fourth injection. Eleven weeks after 
stopping therapy, facial angioedemas reoccurred (Fig. 1). 
Table 2 Comparison of the therapies most often applied in InH-AAE
cr complete remission, pr partial remission, nr no response, NA not available, FFP fresh frozen plasma
Reference Number  
of patients
Drug/doses Response: cr/pr/nr 
(number of patients)
Medical influence of coagulation and contact activation pathway
Tranexamic acid [9] 2 1–4 g per day cr 2
[10] 1 NA cr 1
[11] 15 0.5–3 g per day cr 8/pr 7
[12] 23 0.5–3 g per day cr 12/pr 11
[13] 19 1–3 g per day cr 4/pr 15
[3] 38 0.5–3 g per day pr 37/nr 1
Ecallantide [15] 1 30 mg (during attacks) cr 1
[16] 1 30 mg (during attacks) cr 1
[14] 1 NA pr 1
Icatibant [17] 1 30 mg (during attacks) cr 1
[18] 1 30 mg (during attacks) cr 1
[14] 1 NA pr 1
[19] 2 30 mg (during attack) pr 2
C1-INH [14] 1 1000U twice weekly cr 1
[19] 2 NA pr 2
[20] 1 1000U twice weekly cr 1
Medical influence of the hormonal axis
Progestin [21] 20 Various dosages depending the progestin cr 6/pr 10/nr 4
Medical influence of IgE antibodies and mast cell (Omalizumab)
Omalizumab [46] 3 300 mg every 3–4 weeks; 375 mg every 2 weeks Cr 3
[23] 1 300 mg every 4 weeks initially, then reduced to 
300 mg every 8 weeks
cr 1
[24] 1 300 mg every 4 weeks cr 1
[25] 8 300 mg every 4 weeks initially, then reduced to doses 
and intervals according to symptoms
cr 8
[27] 2 375 mg every 2 weeks initially, then reduced to 
375 mg every 4 weeks
cr 2
[26] 5 300 mg every 2–4 weeks cr 5
Other immunosuppressants or immunomodulatory therapies
Dapsone [29] 1 50 mg per day cr 1
Ciclosporin [28] 1 300 mg per day nr 1
FFP [30] 1 4 units cr 1
Rituximab [31] 1 560 mg (375 mg/m2 body surface area) weekly for 
4 weeks
cr 1
Cannabis [32] 1 20 g per month, inhaled 2–3× per week cr 1
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Omalizumab 150  mg was resumed and the angioedema 
disappeared after 1  week. The patient stayed symptom-
free. The interval between injections was stretched to 
every 2  months and the patient stayed symptom-free 
with only intermittent discrete eyelid swellings.
Patient 2
A 46-year-old white male suffering for 9  years from 
weekly recurrent non-itchy angioedemas on the feet, face 
and tongue. Due to laryngeal angioedema with airway-
occlusion, emergency treatment was necessary in 2013. 
Suggested triggers were mechanical stress, cold, infec-
tions, and NSAIDs. Following a job change with associ-
ated mental pressure, angioedemas were not controllable 
with high doses of AH. Treatment with omalizumab was 
started, using 300 mg s.c. at monthly intervals. Concomi-
tant AH intake was reduced and finally completely dis-
continued after 2  weeks. After 1  year of treatment, the 
dose was reduced to 150  mg and has been given every 
month since, without recurrence of symptoms.
Patient 3
A 27-year-old white female suffering for 8 months from 
weekly recurrent angioedema of the lips and periorbital 
region without pruritus. No trigger factors were noticed. 
Since swelling episodes were not controllable with AH 
and GCS, doses of 300  mg  s.c. of omalizumab were 
initiated at intervals of every 4  weeks. After the second 
injection no further angioedema episodes occurred.
FcεRI‑receptor density in patient 1
Density of FcεRI receptor on basophils was monitored in 
patient 1 (ADR-AC GmbH, Bern, Switzerland). Density 
decreased remarkably from 74,051.61 to 10,892.93  rpc 
after the second injection of omalizumab 150 mg. After 
the 4th injection, after which omalizumab was discontin-
ued, FcεRI-receptor density increased up to 21,666.53 rpc 
during the 16-week pause. After reintroduction of 
omalizumab 150  mg at intervals of 4 to 8  weeks over 
31  months, the FcεRI-receptor density decreased to a 
minimal level of 1,907rpc (see Fig. 2).
Discussion
In 2014 an international working group proposed a clas-
sification of angioedemas without wheals [4]. However, 
characterisation and differentiation of InH-AAE remain 
difficult and evidence of treatment efficacy is limited to 
case reports and uncontrolled small case series. Based 
on the literature, a wide range of different therapies are 
used for InH-AAE. TA is the most frequently used ther-
apy for Inh-AAE. It inhibits plasminogen activation and 
therefore limits FXIIa activation and C1-INH consump-
tion by plasmin. This leads to a decrease of bradykinin 
formation [33, 34]. In the trials described, about one 
Fig. 1 Medication use during treatment with omalizumab in patient 1. Red solid line Omalizumab injections; black solid line Prednisone intake; blue 
solid line Cetirizine intake; green solid line Ketotifen intake. Average doses of AH and oral glucocorticoids were calculated for every month in the past 
two and a half years
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third of the 98 patients had a complete response to TA 
as prophylaxis for InH-AAE [3, 9–13]. Both ecallantide, a 
kallikrein receptor antagonist, and C1-INH, a serine pro-
tease with inhibitory activities in the complement system 
and the contact-,coagulation-, and fibrinolytic pathways, 
reduce the generation of Bradykinin. Ecallantide was 
effective in all described patients with Inh-AAE for acute 
attacks. C1-INH was effective for acute attacks and was 
also valuable for long term prophylaxis [14–16, 19, 20]. 
Icatibant, a competitive bradykinin B2 receptor antago-
nist, selectively prevents the effect of bradykinin on the 
endothelium. Used in acute attacks, it showed a good but 
short-lived response in most of the patients. Progestin 
modulates endogenous oestrogen and therefore reduces 
activation of FXII and the contact activation pathway 
which leads to a control of angioedema in HAE patients 
with C1-Inh deficiency [35, 36]. Saule et al. [21] reported 
favourable experience with progestins to prevent attacks 
in any type of non-allergic angioedema. Omalizumab, a 
humanized IgG monoclonal antibody directed against 
IgE antibodies reduces free IgE levels which results in the 
downregulation of FcεRI receptors on basophils and mast 
cells [37, 38]. Given the current state of knowledge, these 
effects prevent IgG autoantibodies from cross-linking 
FcεRI receptors, cell activation is suppressed, the thresh-
old of mast cell degranulation is increased, and possible 
autoreactive IgE antibodies can not longer bind the high 
affinity receptor [39, 40]. In the described case reports 
and case series all patients diagnosed with Inh-AAE 
responded to omalizumab.
With regard to the mode of action of the different 
medications against InH AAE, the drug either interacts 
with IgE antibodies and influences the mast cells, as does 
omalizumab, or it interacts with the coagulation and 
contact activation pathway, as do tranexamic acid (TA), 
icatibant, ecallantide, C1-INH and progestin (compare 
Table  2). This indicates that mast cells and the contact 
activation pathway are linked by mediators most probably 
secreted by mast cells. As recently discovered, heparin 
from activated mast cells induces the contact activation 
pathway by FXII [41]. These findings beg the conclu-
sion that activated mast cells not only induce histamine 
induced angioedemas by secreting their mediators.
About 40–50% of patients with chronic spontane-
ous urticaria (CSU) have episodes of angioedema and a 
part of them show the symptoms of angioedema with-
out wheals. IH-AAE shares a lot of similarities with CSU. 
Many patients with CSU remain symptomatic in spite of 
antihistamine therapy up to four times the approved dose 
[42, 43]. In these patients ciclosporin and omalizumab 
are recommended as an addon therapy. When IH-AAE 
is associated with CSU responding to antihistamines, 
Inh-AAE should be associated with CSU patients not 
responding to antihistamines.
Fig. 2 Long-term therapy treatment of density of FcεRI-receptors on basophils in patient 1. Red solid line Omalizumab injections; blue solid line 
FcεRI-receptor density. Receptor density decreased substantially during treatment with omalizumab over 31 months from 74,051 receptors per cell 
before start of treatment, to 1,907 receptors per cell
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All three patients described in this report had full 
remission after the second injection of omalizumab 
and remained free of symptoms when omalizumab was 
given continuously. This is in line with the described 
case reports and series so far, where all patients treated 
with omalizumab had a complete response. In patient 1 
we were able to document the decrease of receptor den-
sity in correlation with clinical response (Figs. 1, 2). The 
follow-up of FcεRI-receptor density on basophils over 
31  months showed an impressive continuous decrease 
of receptor density when omalizumab was regularly 
administered and it allowed us to adapt the therapy 
individually.
Strength and limitations
In this study a comprehensive overview of the literature 
of the different treatments in Inh-AAE could be pro-
vided. However, a deficiency lies in the fact that the effect 
of medications interacting with the contact activation 
pathway in the same patients who responded to omali-
zumab was not examined. Another downside of the study 
is that the long term course of FcεRI-receptor density was 
demonstrated in one patient only.
Conclusion
InH-AAE shares similarities to patients with CSU which 
do not respond to antihistamines. Omalizumab is the 
most promising therapeutic approach for prophylaxis in 
Inh-AAE. Not only is histamine involved in the forma-
tion of angioedemas, but also other mediators of acti-
vated mast cells which interact with the contact pathway.
As the clinical course corresponds with FcεRI-receptor 
density [39], this receptor could be evaluated as a bio-
marker to monitor the therapeutic effect and adjust the 
dose of omalizumab for long term therapy.
Better knowledge about how and why mast cells are 
activated and release their mediators more or less selec-
tively, will enable us to design new and more personal-
ized therapies [44, 45].
Abbreviations
AE: angioedema; C1-INH-HAE: hereditary angioedema with C1 inhibitor 
deficiency; IH-AAE: idiopathic histaminergic acquired angioedema; InH-AAE: 
idiopathic non-histaminergic acquired angioedema; AH: antihistamines; GCS: 
glucocorticosteroids; PBMCs: peripheral blood mononuclear cells; rpc: recep-
tor per cell.
Authors’ contribution
MB: analyzed the patients’ histories; accumulation, analysis and interpretation 
of data; revised the manuscript; TP: conducted the FcεRI receptor density 
measurement; revised the manuscript; US: carried out the concept and design 
Additional file
Additional file 1. The detailed search protocol for Medline.
of the study; accumulation, analysis and interpretation of data, revised the 
manuscript; AH: analyzed the patients’ histories; revised the manuscript. All 
authors read and approved the final manuscript.
Author details
1 Department of Clinical Immunology, University Hospital Zurich, Gloriastrasse 
23, 8091 Zurich, Switzerland. 2 Adverse Drug Reaction-Analysis and Consulting 
(ADR-AC) GmbH, Bern, Switzerland. 3 Department of Rheumatology, Immunol-
ogy and Allergology, Inselspital, University Bern, Bern, Switzerland. 
Acknowledgements
The authors would like to thank Dr. Martina Gosteli, main library, University of 
Zurich, for the literature search.
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
All data generated or analysed during this study are included in this published 
article.
Ethics approval and consent to participate
The local Ethical Review Board of Zurich offered a waiver for this study 
(Req-2016-00692). All patients were verbally informed and gave their written 
informed consent for this study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 23 December 2016   Accepted: 17 July 2017
References
 1. Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373–
88 (quiz 389–392).
 2. Aberer W. Angioedema is not just ‘deep urticaria’ but an entity of its own. 
Allergy. 2014;69:549–52.
 3. Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, Stieber C, 
Cichon S, Cicardi M. Presentation, diagnosis and treatment of angi-
oedema without wheals: a retrospective analysis of a cohort of 1058 
patients. J Intern Med. 2015;277:585–93.
 4. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Far-
kas H, Grumach A, Kaplan AP, et al. Classification, diagnosis, and approach 
to treatment for angioedema: consensus report from the Hereditary 
Angioedema International Working Group. Allergy. 2014;69:602–16.
 5. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, 
Cicardi M. Angioedema without urticaria: a large clinical survey. CMAJ. 
2006;175:1065–70.
 6. Farkas H, Veszeli N, Kajdácsi E, Cervenak L, Varga L. “Nuts and bolts” 
of laboratory evaluation of angioedema. Clin Rev Allergy Immunol. 
2016;51:140–51.
 7. Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, 
Chatain C, Deroux A, Bouillet L. Idiopathic histaminergic angioedema 
without wheals: a case series of 31 patients. Clin Exp Immunol. 
2016;185:81–5.
 8. World Medical Association. Declaration of Helsinki ethical princi-
ples for medical research involving human subjects. J Am Coll Dent. 
2014;81:14–8.
 9. Thompson RA, Felix-Davies DD. Response of ‘idiopathic’ recurrent 
angioneurotic oedema to tranexamic acid. BMJ. 1978;2:608.
 10. Hakansson OM. Menstruation-related angioedema treated with 
tranexamic acid. Acta Obstet Gynecol Scand. 1988;67:571–2.
 11. Cicardi M, Bergamaschini L, Zingale LC, Gioffre D, Agostoni A. Idiopathic 
nonhistaminergic angioedema. Am J Med. 1999;106:650–4.
 12. Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic 
acid in sporadic idiopathic bradykinin angioedema. Allergy. 2010;65:793–5.
Page 7 of 7Bucher et al. Clin Transl Allergy  (2017) 7:27 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 13. Wintenberger C, Boccon-Gibod I, Launay D, Fain O, Kanny G, Jeandel PY, 
Martin L, Gompel A, Bouillet L. Tranexamic acid as maintenance treat-
ment for non-histaminergic angioedema: analysis of efficacy and safety 
in 37 patients. Clin Exp Immunol. 2014;178:112–7.
 14. Stahl MC, Harris CK, Matto S, Bernstein JA. Idiopathic nonhistaminergic 
angioedema successfully treated with ecallantide, icatibant, and C1 ester-
ase inhibitor replacement. J Allergy Clin Immunol Pract. 2014;2:818–9.
 15. Berry A, Firszt R. Successful treatment of idiopathic angioedema with 
ecallantide. J Allergy Clin Immunol Pract. 2013;1:297–8.
 16. Dy TB, Rasheed M, Parikh P, Bernstein L. Resolution of an acute attack of 
idiopathic angioedema with ecallantide. Ann Allergy Asthma Immunol. 
2013;111:224–6.
 17. Del Corso I, Puxeddu I, Sardano E, Geraci S, Breggia M, Rocchi V, Migliorini 
P. Treatment of idiopathic nonhistaminergic angioedema with brady-
kinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol. 
2012;108:460–1.
 18. Montinaro V, Loizzo G, Zito A, Castellano G, Gesualdo L. Successful treat-
ment of a facial attack of angioedema with icatibant in a patient with 
idiopathic angioedema. Am J Emerg Med. 2013;31:1295.e1295–6.
 19. Shroba J, Hanson J, Portnoy J. Current treatment options for idiopathic 
angioedema. Ann Allergy Asthma Immunol. 2015;115:429–33.
 20. Gravante C, Carucci L, Bova M, Petraroli A, Genovese A, Marone G. 
Prophylactic treatment with plasma-derived C1 inhibitor in idiopathic 
non-histaminergic angioedema. Pediatr Allergy Immunol. 2016;27:658–9.
 21. Saule C, Boccon-Gibod I, Fain O, Kanny G, Plu-Bureau G, Martin L, Launay 
D, Bouillet L, Gompel A. Benefits of progestin contraception in non-
allergic angioedema. Clin Exp Allergy. 2013;43:475–82.
 22. Sands MF, Blume JW, Schwartz SA. Successful treatment of 3 patients 
with recurrent idiopathic angioedema with omalizumab. J Allergy Clin 
Immunol. 2007;120:979–81.
 23. von Websky A, Reich K, Steinkraus V, Breuer K. Complete remission of 
severe chronic recurrent angioedema of unknown cause with omali-
zumab. J Dtsch Dermatol Ges. 2013;11:677–8.
 24. Ozturk AB, Kocaturk E. Omalizumab in recurring larynx angioedema: a 
case report. Asia Pac Allergy. 2014;4:129–30.
 25. Azofra J, Díaz C, Antépara I, Jaúregui I, Soriano A, Ferrer M. Posi-
tive response to omalizumab in patients with acquired idiopathic 
nonhistaminergic angioedema. Ann Allergy Asthma Immunol. 
2015;114:418e411–419e411.
 26. Faisant C, Du Thanh A, Mansard C, Deroux A, Boccon-Gibod I, Bouillet L. 
Idiopathic non-histaminergic angioedema: successful treatment with 
omalizumab in five patients. J Clin Immunol. 2016;37:80–4.
 27. Munoz JP, Casado AF, Taboada AC, Campos Munoz L, Bran EL. Success-
ful treatment of refractory idiopathic angio-oedema with omalizumab: 
review of the literature and function of IgE in angio-oedema. Clin Exp 
Dermatol. 2016;41:399–402.
 28. Şener O, Bolu E, Akyol S. Cyclosporine A in the treatment of chronic idi-
opathic angioedema: a case report. Gulhane Med J. 2005;47:228–30.
 29. Gonzalez P, Soriano V, Caballero T, Niveiro E. Idiopatic angioedema treated 
with dapsone. Allergol Immunopathol. 2005;33:54–6.
 30. Franzen D, Ursprung T, Wuthrich B, Reber A. Idiopathic non-histaminergic 
angio-oedema after routine extubation successfully treated with fresh 
frozen plasma. Anaesthesia. 2006;61:698–701.
 31. Ghazan-Shahi S, Ellis AK. Severe steroid-dependent idiopathic angi-
oedema with response to rituximab. Ann Allergy Asthma Immunol. 
2011;107:374–6.
 32. Frenkel A, Roy-Shapira A, Evgeni B, Leonid K, Borer A, Klein M. Life threat-
ening idiopathic recurrent angioedema responding to cannabis. Case 
Rep Immunol. 2015;2015:780824.
 33. Tengborn L, Blomback M, Berntorp E. Tranexamic acid—an old drug still 
going strong and making a revival. Thromb Res. 2015;135:231–42.
 34. Kaplan AP, Joseph K. Complement, Kinins, and hereditary angioedema: 
mechanisms of Plasma Instability when C1 Inhibitor is Absent. Clin Rev 
Allergy Immunol. 2016;51:207–15.
 35. Citarella F, Misiti S, Felici A, Farsetti A, Pontecorvi A, Fantoni A. Estrogen 
induction and contact phase activation of human factor XII. Steroids. 
1996;61:270–6.
 36. Bork K, Fischer B, Dewald G. Recurrent episodes of skin angioedema 
and severe attacks of abdominal pain induced by oral contraceptives or 
hormone replacement therapy. Am J Med. 2003;114:294–8.
 37. MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, 
McKenzie-White J, Sterbinsky SA, Hamilton RG, Lichtenstein LM. Down-
regulation of Fc(epsilon)RI expression on human basophils during 
in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 
1997;158:1438–45.
 38. Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-
induced reductions in mast cell Fce psilon RI expression and function. J 
Allergy Clin Immunol. 2004;114:527–30.
 39. Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-
Chess J, Jarvis P, Georgiou P, Canvin J, et al. Clinical efficacy of omali-
zumab in chronic spontaneous urticaria is associated with a reduction of 
FcepsilonRI-positive cells in the skin. Theranostics. 2017;7:1266–76.
 40. Kaplan AP, Gimenez-Arnau AM, Saini SS. Mechanisms of action that 
contribute to efficacy of omalizumab in chronic spontaneous urticaria. 
Allergy. 2017;72:519–33.
 41. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, 
Burfeind P, Cichon S, Hammerschmidt S, et al. Mast cells increase vascular 
permeability by heparin-initiated bradykinin formation in vivo. Immunity. 
2011;34:258–68.
 42. Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, 
Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, et al. Unmet 
clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force 
report. Allergy. 2011;66:317–30.
 43. Guillen-Aguinaga S, Jauregui Presa I, Aguinaga-Ontoso E, Guillen-Grima F, 
Ferrer M. Updosing nonsedating antihistamines in patients with chronic 
spontaneous urticaria: a systematic review and meta-analysis. Br J Derma-
tol. 2016;175:1153–65.
 44. Theoharides TC, Kempuraj D, Tagen M, Conti P, Kalogeromitros D. Differ-
ential release of mast cell mediators and the pathogenesis of inflamma-
tion. Immunol Rev. 2007;217:65–78.
 45. Harvima IT, Levi-Schaffer F, Draber P, Friedman S, Polakovicova I, Gibbs 
BF, Blank U, Nilsson G, Maurer M. Molecular targets on mast cells and 
basophils for novel therapies. J Allergy Clin Immunol. 2014;134:530–44.
